NEC OncoImmunity AS Revenue and Competitors

Claim your profile

Oslo, Norway

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NEC OncoImmunity AS's estimated annual revenue is currently $3.7M per year.(i)
  • NEC OncoImmunity AS's estimated revenue per employee is $155,000

Employee Data

  • NEC OncoImmunity AS has 24 Employees.(i)
  • NEC OncoImmunity AS grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.5M8730%N/AN/A
#2
$2.6M17-45%N/AN/A
#3
$2.6M176%N/AN/A
#4
$9.1M599%N/AN/A
#5
$3.7M249%N/AN/A
#6
$6.8M4416%N/AN/A
#7
$11.8M7627%N/AN/A

OncoImmunity AS is a Norwegian company established to develop bioinformatics software that has the ability to empower precision cancer immunotherapy, and thus improve the outlook for patients with late-stage disease. We develop machine-learning methods, accessible online, applied to genomics data for tumor immune profiling. The company has just successfully completed a funding round and has attracted significant investment from both life science and software investors. The company's first software product offering will select optimal patients to be assigned to cancer immunotherapy clinical trials. In addition the software can identify mutated peptides in cancer with potential for patient monitoring, companion diagnostics and can be used to develop more personalized cancer immunotherapies. The company is located in the dynamic Oslo Cancer Cluster Innovation Park, which is home to a synergistic ecosystem of organizations that include the Cancer Registry of Norway, the Oslo Cancer Cluster Incubator, the Institute for Medical Informatics and Pathology and a mix of local biotech and global pharma companies.

keywords:N/A

N/A

Total Funding

24

Number of Employees

$3.7M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NEC OncoImmunity AS News

2022-04-06 - CEPI to help NEC Corporation develop broad protection ...

NEC OncoImmunity AS (NOI) specializes in artificial intelligence (AI)-driven biotechnology, which will be used to develop these vaccines.

2022-03-30 - NEC : CEPI partners with Japan's NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine

CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in...

2022-03-30 - CEPI partners with Japan's NEC Group for AI-designed ...

CEPI will provide seed funding of up to $4.8 million to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.4M24-8%N/A
#2
$2.5M2460%N/A
#3
$2.4M24-23%N/A
#4
$2.4M24100%N/A
#5
$3.7M2579%N/A